Fig. 5

Identification of new druggable targets and repurposing of FDA-approved drugs. A. Druggable targets prioritization strategy. B. Scatterplot showing drug targets ranked according to the Druggability Score. C. MTT assay on K562 and K562-R cells exposed for 24 h at different concentrations of FDA-approved inhibitors of prioritized targets. MK-2206 (AKTi) was used as a negative control. The graphs show the percentage of absorbance at 595 nm normalized on control condition. The reported statistical significance is between K562 and K562-R cells at the same experimental condition